Copd News

Mike is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.

In a bid to stay competitive in treating respiratory diseases, AstraZeneca is paying up to $1.15 billion for the privately held biotech firm Pearl Therapeutics .

Women are 37 percent more likely to have chronic obstructive pulmonary disease than men and now account for more than half of all deaths attributed to COPD in our nation.

People with chronic obstructive pulmonary disease who have signs of chronic inflammation in their blood are more likely to have flare-ups of the lung disease than those who do not, a large new study shows.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! 11 June 2013 -- Recipharm AB is pleased to announce that it is working with Vectura Group plc to provide access to its licence for the regulatory dossier of AsmasalA for the Chinese regulatory authorities as part of the Chinese market approval process.

Smart Nasal Cannula: Big technology Change, Plus a New Product Launch Model for Oxyview --GSA Interest: Department of Interior protecting America's Natural Resources --Framework of Oxyview-Targeting Efficient Respiratory Consumption --A New Business Model for Smart Nasal Cannula Medical Technology --Multi-Media Presentations, Ingen website Oxyview ... (more)

AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.

Women are 37 percent more likely to have chronic obstructive pulmonary disease than men and now account for more than half of all deaths attributed to COPD in our nation.

Women are 37 percent more likely to have chronic obstructive pulmonary disease than men and now account for more than half of all deaths attributed to COPD in our nation.

Ockham Overturns Vectura Group plc 's Challenge to Secure European Patent Rights for Inhaled Heparin in the Treatment of COPD Staying up-to-date has never been simpler.

The US Food and Drug Administration has published an update informing users that the remaining two inhalers for the treatment of asthma and chronic obstructive pulmonary disease containing chloroflurocarbons , will soon be taken off the market.

"We say: ' Quit now!' You can do it with the right support!" said Angela Francis, chief executive of the Asthma Foundation.

We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records.

A Washington, D.C., reporter for more than 30 years, Jim Limbach covers the federal agencies for ConsumerAffairs.

The last two inhalers in the U.S. that contain ozone-damaging chloroflurocarbons will be taken off the market before the end of this year.

A team from various Swiss research centers and hospitals conducted a study of more than 300 patients hospitalized with acute exacerbations of COPD.

"[A]n agreement of confidentiality, or circumstances creating a similar expectation of secrecy, may negate a 'public use' where there is not commercial exploitation" [even] when an unaffiliated third party is responsible for the allegedly public use.

People who are consistently exposed to both wood smoke and tobacco smoke are at a greater risk for developing chronic obstructive pulmonary disease and for experiencing more frequent and severe symptoms of the disease, as well as more severe airflow obstruction, than those who are exposed to only one type of smoke, according to the results of a new ... (more)

Researchers found that over 40 percent of patients being treated for COPD at federally funded clinics did not actually have the disease.

First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design , has initiated a Phase 2 clinical study with PSX1002 that will ... (more)